Novartis’ Multiple Sclerosis Pill Slowed Brain Loss in Study

Novartis AG said its Gilenya drug to treat multiple sclerosis helped slow brain loss, a measure linked to the severity of the disease.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.